Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Drug Delivery Performance and Fugitive Emission Comparison of Two Commercially Available Nebulizer Systems

Mark Nagel, Nathaniel Hoffman, Jason Suggett
European Respiratory Journal 2021 58: PA3402; DOI: 10.1183/13993003.congress-2021.PA3402
Mark Nagel
1Trudell Medical International, London (ON), Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mnagel@trudellmed.com
Nathaniel Hoffman
1Trudell Medical International, London (ON), Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason Suggett
1Trudell Medical International, London (ON), Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

Background: Delivery of inhaled medications by nebulizer for the treatment of respiratory disease is widespread. Important factors to consider in a delivery system are amount and consistency of drug delivered to the lungs as well as the amount of drug/droplets that are emitted to the local environment (Fugitive Emissions).

Methodology: Nebulizers (AEROECLIPSE* II Breath Actuated Nebulizer (BAN) and Aerogen* Ultra) were evaluated with 2.5mg/3.0mL fill of salbutamol and connected to a breathing simulator mimicking adult tidal volume (500-ml) with I/E ratios of 1:1, 1:2 and 1:3. Emitted aerosol was captured by filter at 1-minute intervals until sputtering to determine total mass (TMsal). The percentage of drug mass lost to the environment (ELsal) was determined by combining the TMsal recovered from the inhalation filters along with the residual mass recovered from the nebulizer and subtracting that from the initial 2.5mg salbutamol placed in the nebulizer. Salbutamol assay was undertaken by HPLC. Fine droplet mass (FDMSal µg) was determined by laser diffractometry as the product of TMsal and fine droplet fraction (%<4.7µm)

Results: Average +/- SD FDMsal and ELsal at extended I/E ratios are reported in the table.

I:E RatioAEROECLIPSE®II BANAerogen* Ultra
FDMsal(µg)ELsal(%)FDMsal(µg)ELsal(%)
1:1803±764.1±1.0503±3123.8±1.6
1:2715±825.2±2.7316±1234.0±2.8
1:3695±524.2±1.3234±1337.4±3.4

Conclusions: Higher and more consistent delivery was achieved by BAN as well as lower fugitive emissions. Clinicians should be aware of the ability to get increased amounts of medication to the lungs while maintaining a safer work environment for staff with use of the BAN.

  • Asthma - management
  • Pharmacology
  • Bronchodilators

Footnotes

Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3402.

This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

  • Copyright ©the authors 2021
Previous
Back to top
Vol 58 Issue suppl 65 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Drug Delivery Performance and Fugitive Emission Comparison of Two Commercially Available Nebulizer Systems
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Drug Delivery Performance and Fugitive Emission Comparison of Two Commercially Available Nebulizer Systems
Mark Nagel, Nathaniel Hoffman, Jason Suggett
European Respiratory Journal Sep 2021, 58 (suppl 65) PA3402; DOI: 10.1183/13993003.congress-2021.PA3402

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Drug Delivery Performance and Fugitive Emission Comparison of Two Commercially Available Nebulizer Systems
Mark Nagel, Nathaniel Hoffman, Jason Suggett
European Respiratory Journal Sep 2021, 58 (suppl 65) PA3402; DOI: 10.1183/13993003.congress-2021.PA3402
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Figures & Data
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations
  • Late Breaking Abstract - First-time assessment of efficacy of candidate vaccine to prevent acute exacerbations of chronic obstructive pulmonary disease (AECOPD): multicentre, randomised, controlled, observer-blind phase 2b trial
  • Identifying super-responders to benralizumab in severe asthma
Show more Airway pharmacology and treatment

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society